Hester BiosQ1 FY25

Hester Bios Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹2,324.6P/E: 33.7Market Cap: ₹2.0K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

No

1 of 4 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2
  • Q1 FY25 showed strong foundation with 36% quarter-on-quarter standalone sales growth and 34% consolidated sales growth.
  • Poultry Healthcare division grew 35% in Q1, driven by recovery in the poultry industry and focus on vaccines.
  • Animal Healthcare division saw 41% growth, boosted by positive dairy sector trends.
  • Petcare division achieved 29% growth, with increased penetration in vet clinics and new product launches.
  • Africa business is expected to grow geometrically, with improving orders and distribution network.
  • Capacity expansions in India (freeze-drying capacity doubling) expected by Q3 FY25 to support higher volumes without new CAPEX.
  • Launch of Avian Influenza Vaccine expected in Q4 FY25 or Q1 FY26 expected to drive future poultry vaccine growth.
  • Management optimistic about sustaining upward topline and bottom-line trends through FY25 and beyond, without giving formal guidance.

See what Hester Bios management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • As per the transcript of the earnings call held on 2 August 2024, Hester Biosciences mentioned that:
  • - The current capacity utilization in India is near full, and the CAPEX for expansion has already been incurred.
  • - There is no planned CAPEX for increasing capacity in Africa or Nepal at this point.
  • - They do not foresee the need for additional spending on capacity in the near term.
  • There was no mention or indication of any new fundraising plans through debt or equity in the current or near future.
  • The company emphasized focusing on optimizing existing capacity and maintaining an upward trend in revenues and margins without additional capital raising.

See what Hester Bios management said on order book — free account, 30 seconds.

Capex plans

No
  • No additional CAPEX planned for Africa and Nepal; existing capacities deemed sufficient.
  • In India, the company recently expanded capacity; related CAPEX has already been incurred.
  • The expanded capacity at the India facility, including increased freeze-drying capacity, will come into operation in Q3 FY25.
  • Minor modifications planned to repurpose a BSL-3 facility (originally for COVID bulk antigen) for animal vaccines without significant CAPEX.
  • Focus on leveraging existing capacity and pipeline products rather than major new capital investments.
  • No specific investment planned in the pet division currently; focus is on introducing new healthcare-related products rather than CAPEX.
  • Strategic investments include building distribution channels in Africa via subsidiary and invested company Trishul Exim.

Track Hester Bios — get its next earnings analysis in your feed

How does Hester Bios rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisHester Bios
Rev 2Mar 3

How does Hester Bios rank in Pharmaceuticals & Biotechnology?

Compare Hester Bios against every Pharmaceuticals & Biotechnology company (Q1 FY25) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →